DE69518642D1 - Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c - Google Patents

Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c

Info

Publication number
DE69518642D1
DE69518642D1 DE69518642T DE69518642T DE69518642D1 DE 69518642 D1 DE69518642 D1 DE 69518642D1 DE 69518642 T DE69518642 T DE 69518642T DE 69518642 T DE69518642 T DE 69518642T DE 69518642 D1 DE69518642 D1 DE 69518642D1
Authority
DE
Germany
Prior art keywords
sub
seq
hepatitis
cytotoxic
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69518642T
Other languages
English (en)
Other versions
DE69518642T2 (de
DE69518642T3 (de
Inventor
V Chisari
Andreas Cerny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22799919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69518642(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of DE69518642D1 publication Critical patent/DE69518642D1/de
Publication of DE69518642T2 publication Critical patent/DE69518642T2/de
Application granted granted Critical
Publication of DE69518642T3 publication Critical patent/DE69518642T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69518642T 1994-03-17 1995-03-16 Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c Expired - Lifetime DE69518642T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/214,650 US5709995A (en) 1994-03-17 1994-03-17 Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US214650 1994-03-17
PCT/US1995/003224 WO1995025122A1 (en) 1994-03-17 1995-03-16 Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus

Publications (3)

Publication Number Publication Date
DE69518642D1 true DE69518642D1 (de) 2000-10-05
DE69518642T2 DE69518642T2 (de) 2001-05-03
DE69518642T3 DE69518642T3 (de) 2009-05-14

Family

ID=22799919

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69518642T Expired - Lifetime DE69518642T3 (de) 1994-03-17 1995-03-16 Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c

Country Status (7)

Country Link
US (2) US5709995A (de)
EP (1) EP0759937B2 (de)
JP (3) JP3844494B2 (de)
AT (1) ATE195953T1 (de)
CA (1) CA2184890C (de)
DE (1) DE69518642T3 (de)
WO (1) WO1995025122A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
CA2162557C (en) 1993-05-12 2004-09-28 Amy J. Weiner Conserved motif of hepatitis c virus e2/ns1 region
US6555114B1 (en) * 1993-11-04 2003-04-29 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
EP0804469B1 (de) * 1995-01-16 2001-11-28 Northern Sydney Area Health Service T-Zellen beeinflussende Peptide
EP0921805A4 (de) * 1996-03-19 2002-06-26 Univ Virginia Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
AU2658897A (en) * 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
EP1767542B1 (de) * 1996-03-21 2016-05-11 Epimmune Inc. HLA-A2.1 bindende Peptide und deren Verwendung
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
ATE357526T1 (de) * 1998-08-21 2007-04-15 Us Gov Health & Human Serv Modifizierte hcv peptid-impfstoffe
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US20090130135A1 (en) * 1999-10-01 2009-05-21 Michael Buschle Hcv vaccines
JP2003511420A (ja) * 1999-10-13 2003-03-25 カイロン コーポレイション タンパク質から細胞性免疫応答を得る方法
CN101684146A (zh) * 1999-11-24 2010-03-31 诺华疫苗和诊断公司 新颖的hcv非结构多肽
US6986892B1 (en) 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
KR100879810B1 (ko) * 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 아밀로이드의 하향-조절을 위한 신규한 방법
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
IL142802A (en) * 2000-04-27 2015-01-29 Enzo Therapeutics Inc Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
WO2001093804A2 (en) * 2000-06-02 2001-12-13 Merck & Co., Inc. Hepatitis c virus conjugates
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
WO2002020616A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla-a2.1 binding peptides and their uses
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
US7097837B2 (en) * 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
AU2002259130A1 (en) 2001-05-03 2002-11-18 Eli Lilly And Company Agents for treatment of hcv and methods of use
US20030224011A1 (en) * 2001-05-29 2003-12-04 Conley Anthony J Hepatitis c virus conjugates
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AU2003301865A1 (en) * 2002-05-16 2004-06-07 The General Hospital Corporation Epitopes of hepatitis c virus
FR2839722A1 (fr) * 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
AU2003258672B2 (en) 2002-09-13 2008-10-30 Intercell Ag Method for isolating hepatitis C virus peptides
ES2543084T3 (es) 2003-02-18 2015-08-14 Baylor College Of Medicine Activación inducida en células dendríticas
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
CN1822856B (zh) 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
FR2862648B1 (fr) * 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
CA2566506A1 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
CA2608193A1 (en) * 2005-05-11 2006-11-23 The Trustees Of The University Of Pennsylvania Methods for the rapid expansion of antigen specific t-cells
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EP1976981A2 (de) * 2005-11-10 2008-10-08 The University Of Chicago Hcv-reaktive t-zellrezeptoren
CN101336110B (zh) 2006-06-01 2011-06-01 程云 预防或治疗肝损伤的肽及其衍生物及其应用
CA2666667C (en) * 2006-10-19 2023-06-20 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
EP2331680B1 (de) 2008-09-22 2017-05-03 Baylor College Of Medicine Verfahren und zusammensetzungen zur erzeugung einer immunreaktion mittels cd40-induktion sowie strukturerkennungsrezeptoradaptern
WO2010039224A2 (en) * 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
AU2010280981B2 (en) * 2009-08-05 2016-01-28 Nexigen Gmbh Human HCV-interacting proteins and methods of use
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP5930967B2 (ja) 2010-09-08 2016-06-08 学校法人 埼玉医科大学 Ｃ型肝炎ウイルスリポソームワクチン
WO2012072088A1 (en) 2010-12-02 2012-06-07 Bionor Immuno As Peptide scaffold design
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
JP2014530009A (ja) 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
CA2860914A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2864354A1 (de) * 2012-06-26 2015-04-29 Apo-T B.V. Gegen pathogene gerichtete bindungsmoleküle
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
JP6541639B2 (ja) 2013-03-14 2019-07-10 ベリカム ファーマシューティカルズ， インコーポレイテッド Ｔ細胞増殖をコントロールするための方法
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
CA2937750A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3189148A4 (de) 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Co-stimulierung von chimären antigenrezeptoren durch myd88- und cd40-polypeptide
EP3215522B1 (de) 2014-11-03 2021-12-01 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Gegen bob1 gerichtete t-zell-rezeptoren und verwendungen davon
CA2978171A1 (en) 2015-03-10 2016-09-15 J.H. Frederik Falkenburg T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
WO2017180420A1 (en) * 2016-04-11 2017-10-19 Board Of Regents, The University Of Texas System Methods and compositions for detecting single t cell receptor affinity and sequence
WO2018055535A2 (en) 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
EP3621988A1 (de) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Verfahren zur verstärkung oder änderung der signaltransduktion
US20200347148A1 (en) 2017-12-08 2020-11-05 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
EP4259163A2 (de) * 2020-12-09 2023-10-18 Tevogen Bio Inc. Virusspezifische t-zellen und verfahren zur behandlung und prävention von virusinfektionen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
US4977092A (en) * 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
DK154394C (da) * 1982-10-21 1989-04-24 Apv Pasilac As Fremgangsmaade til at foroege kapaciteten af anlaeg for membranfiltrering af maelk eller maelkeprodukter til foderstoffer eller vaekstmedier.
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
US4625918A (en) * 1983-07-29 1986-12-02 Diesel Kiki Co., Ltd. Fuel injection valve
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4624918A (en) 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
JPS6137738A (ja) * 1984-07-31 1986-02-22 Tetsuo Nakamura Ｂ型肝炎ワクチン
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
JPH0454197A (ja) * 1990-06-19 1992-02-21 Chemo Sero Therapeut Res Inst Ｃ型肝炎ウイルス抗体検出用合成ペプチド抗原、その組成物およびその使用方法
AU652941B2 (en) * 1990-06-25 1994-09-15 Research Foundation For Microbial Diseases Of Osaka University, The Non-A, Non-B hepatitis virus particles
RO117329B1 (ro) * 1991-06-24 2002-01-30 Chiron Corp Emeryville Polipeptide care contin o secventa a virusului hepatitei c
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
ATE179716T1 (de) 1992-03-06 1999-05-15 Innogenetics Nv Verfahren zur bestimmung von peptiden, die immunologisch wichtigen epitopen von hcv zugehörig sind
US5980899A (en) 1992-06-10 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US6555114B1 (en) * 1993-11-04 2003-04-29 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
AU697171B2 (en) * 1994-04-08 1998-10-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure

Also Published As

Publication number Publication date
DE69518642T2 (de) 2001-05-03
JP3844494B2 (ja) 2006-11-15
JP4394019B2 (ja) 2010-01-06
ATE195953T1 (de) 2000-09-15
CA2184890A1 (en) 1995-09-21
JP2005247852A (ja) 2005-09-15
US7220420B2 (en) 2007-05-22
JPH09510455A (ja) 1997-10-21
EP0759937A1 (de) 1997-03-05
DE69518642T3 (de) 2009-05-14
JP2006265264A (ja) 2006-10-05
JP4463786B2 (ja) 2010-05-19
EP0759937B1 (de) 2000-08-30
WO1995025122A1 (en) 1995-09-21
CA2184890C (en) 2011-05-24
US5709995A (en) 1998-01-20
EP0759937B2 (de) 2008-12-31
US20020115061A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
DE69518642T2 (de) Peptide zur induktion von immunantwort durch zytotoxischen t lymphocyten gegen das virus von hepatitis c
RU2212899C2 (ru) Hcv иммунореактивные полипептидные композиции
EP0979867A3 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
ES2029171A6 (es) Un procedimiento para preparar un polipeptido virico de hepatitis no a y no b post-transfusional (pt-nanbh)
RU98117084A (ru) Hcv иммунореактивные полипептидные композиции
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
MY104208A (en) Non-a, non-b hepatitis virus antigen peptide.
HU9303703D0 (en) Hepatitis c virus (hcv) polypeptides
CA2108466A1 (en) Hcv genomic sequences for diagnostics and therapeutics
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
DE69030124D1 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus
ATE231557T1 (de) Detektion des hepatis-c virus.
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
DE60036881D1 (de) Neues nichtstrukturelles hcv polypeptid
DE69133552D1 (de) Nicht-A, nicht-B Hepatitis Virus Antigen, und diagnostische Verfahren.
WO1995032290A3 (en) Non-a/non-b/non-c/non-d/non-e hepatitis agents and molecular cloning thereof
Honda et al. Sequence comparisons for a hepatitis C virus genome RNA isolated from a patient with liver cirrhosis
GR3015437T3 (en) Non-a non-b sequences.
DE755943T1 (de) Durch Antikörper gegen das C33-Antigen des Hepatitis C-Virus erkennbares Peptid
KR950000880A (ko) 한국형 씨(c)형 간염 바이러스의 일종인 케이에이치씨브이-엘2(khcv-l2)의 전체 뉴클레오티드서열 및 이로부터 유추된 아미노산 서열
KR950000881A (ko) 새로운 한국형 씨(C)형 간염 바이러스 씨디엔에이(cDNA) 절편의 뉴클레오티드 서열 및 이로부터 유추된 아미노산 서열
BR0204599A (pt) Sequências de proteìna de núcleo de hcv
IT1270941B (it) Peptidi di hcv e loro usi.
TH11517EX (th) การใช้แอนติเจนชนิดต่างๆของไวรัสตับอักเสบซี (hcv) ร่วมกัน เพื่อใช้ในการวิเคราะห์ทางอิมมูนสำหรับแอนติ - hcv แอนติบอดี
TW369600B (en) Antigenic peptides for grouping hepatitis C virus, kit comprising the same and methods for its grouping the same

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings